Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gunjan L Shah

Showing results (61-70 of 130) with videos related to

Pageof 13
Sort By:
Blood Cancer Journal|May 27, 2024
Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myelomaBruno Almeida Costa, Jessica Flynn, Noriko Nishimura, et al.
Blood|November 3, 2022
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapyOliver Van Oekelen, Karthik Nath, Tarek H Mouhieddine, et al.
Blood Advances|April 15, 2024
Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapiesAnna J Howard, Isabel Concepcion, Alice X Wang, et al.
Transplantation and Cellular Therapy|March 30, 2021
The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell TherapyMarta Garcia-Recio, Kitsada Wudhikarn, Martina Pennisi, et al.
Haematologica|October 30, 2025
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-RBrian Hess, Alison Moskowitz, James A Davis, et al.
Blood|May 10, 2024
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myelomaRoss S Firestone, Nicholas D Socci, Tala Shekarkhand, et al.
Blood|June 15, 2023
A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphomaMwanasha H Merrill, Parastoo B Dahi, Robert A Redd, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 26, 2026
Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific AntibodiesIssam S Hamadeh, Maximillian Merz, Andriy Derkach, et al.
British Journal of Haematology|August 24, 2023
The Simplified Comorbidity Index predicts non-relapse mortality in reduced-intensity conditioning allogeneic haematopoietic cell transplantationShlomo Elias, Samantha Brown, Sean M Devlin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 23, 2017
The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34<sup>+</sup>-Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic MalignanciesSatyajit Kosuri, Diego Adrianzen Herrera, Michael Scordo, et al.
Pageof 13

Showing results (61-70 of 130) with videos related to

Sort By:
Pageof 13
Blood Cancer Journal|May 27, 2024
Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myelomaBruno Almeida Costa, Jessica Flynn, Noriko Nishimura, et al.
Blood|November 3, 2022
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapyOliver Van Oekelen, Karthik Nath, Tarek H Mouhieddine, et al.
Blood Advances|April 15, 2024
Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapiesAnna J Howard, Isabel Concepcion, Alice X Wang, et al.
Transplantation and Cellular Therapy|March 30, 2021
The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell TherapyMarta Garcia-Recio, Kitsada Wudhikarn, Martina Pennisi, et al.
Haematologica|October 30, 2025
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-RBrian Hess, Alison Moskowitz, James A Davis, et al.
Blood|May 10, 2024
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myelomaRoss S Firestone, Nicholas D Socci, Tala Shekarkhand, et al.
Blood|June 15, 2023
A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphomaMwanasha H Merrill, Parastoo B Dahi, Robert A Redd, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 26, 2026
Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific AntibodiesIssam S Hamadeh, Maximillian Merz, Andriy Derkach, et al.
British Journal of Haematology|August 24, 2023
The Simplified Comorbidity Index predicts non-relapse mortality in reduced-intensity conditioning allogeneic haematopoietic cell transplantationShlomo Elias, Samantha Brown, Sean M Devlin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 23, 2017
The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34<sup>+</sup>-Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic MalignanciesSatyajit Kosuri, Diego Adrianzen Herrera, Michael Scordo, et al.
Pageof 13